Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs IAC/Interactivecorp — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B), while IAC/Interactivecorp trades at $40.94 (market cap $3.02B). The key difference: Iovance Biotherapeutics Inc. Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and IAC/Interactivecorp for 79 Days on average.
| IOVA | PPLI | |
|---|---|---|
Market Cap | $5.85B | $3.02B |
Volume | 14,517,176 | 932,191 |
Sector | Health | Media |
52-Week High | $14.82 | $47.62 |
52-Week Low | $1.81 | $31.52 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $5.78B | $3.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PPLI trades at $40.93, down 0.87% on the day, with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility, including a significant Q2 2026 beat. Fundamentals reveal mixed performance with negative 2025 net income but improving 2026 projections, while valuation metrics appear attractive with P/E of 6.87 and P/B of 0.59.
The outlook remains positive due to potential MGM acquisition interest and improving 2026 profitability projections, though risks include inconsistent earnings history and negative cash flow trends. Institutional sentiment is bullish with no sell ratings, supporting near-term upside potential if acquisition talks materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
